Nevro Corp. (NVRO): Price and Financial Metrics


Nevro Corp. (NVRO)

Today's Latest Price: $171.03 USD

2.06 (1.22%)

Updated Nov 27 1:00pm

Add NVRO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

NVRO Stock Summary

  • With a one year PEG ratio of 324.95, Nevro Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 89.96% of US stocks.
  • With a price/sales ratio of 15.86, Nevro Corp has a higher such ratio than 89.92% of stocks in our set.
  • With a year-over-year growth in debt of 80.28%, Nevro Corp's debt growth rate surpasses 86.5% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Nevro Corp, a group of peers worth examining would be NTRA, CYRX, TWOU, REFR, and XENT.
  • NVRO's SEC filings can be seen here. And to visit Nevro Corp's official web site, go to www.nevro.com.

NVRO Stock Price Chart Interactive Chart >

Price chart for NVRO

NVRO Price/Volume Stats

Current price $171.03 52-week high $175.71
Prev. close $168.97 52-week low $65.05
Day low $167.76 Volume 76,808
Day high $171.44 Avg. volume 398,287
50-day MA $154.28 Dividend yield N/A
200-day MA $130.44 Market Cap 5.89B

Nevro Corp. (NVRO) Company Bio


Nevro Corporation develops and commercializes a neuromodulation platform for the treatment of chronic pain. The company was founded in 2006 and is founded in Menlo Park, California.


NVRO Latest News Stream


Event/Time News Detail
Loading, please wait...

NVRO Latest Social Stream


Loading social stream, please wait...

View Full NVRO Social Stream

Latest NVRO News From Around the Web

Below are the latest news stories about Nevro Corp that investors may wish to consider to help them evaluate NVRO as an investment opportunity.

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

Nevro Initiates Plan for Manufacturing Operations in Costa Rica to Support Future Growth

REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it will establish global manufacturing operations in Costa Rica to…

PR Newswire | September 14, 2020

Liberty All-Star® Growth Fund, Inc. July 2020 Monthly Update

BOSTON , Aug. 14, 2020 /PRNewswire/ -- Below is the July 2020 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG ) Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, July, 2020 Investment Approach: Fund Style: All-Cap Growth Fund Strategy: Combines three growth style investment managers, each with a distinct capitalization focus (small-, mid- and large-cap) selected and continuously monitored by the Fund's Investment Advisor. Investment Managers: Weatherbie Capital, LLC Small-Cap Growth Congress Asset Management Company, LLP Mid-Cap Growth Sustainable Growth Advisers, LP Large-Cap Growth Top 20 Holdings at Month-End (31.0% of equity portfolio) 1 Chegg, Inc. 2.3% 2 FirstService Corp. 2.1% 3 Nevro Corp. 1.9% 4 Paylocity Holding Corp. 1.7% 5 Microsoft Corp. 1....

Benzinga | August 14, 2020

Global Nerve Repair and Regeneration Market Outlook 2020: Company Profiles of Key Players Axogen, Baxter, Nevro, Nuvectra, Polyganics and Stryker - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Nerve Repair and Regeneration - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering. The Global Nerve Repair and Regeneration market accounted for $6.46 billion in 2018 and is expected to reach $21.68 billion by 2027 growing at a CAGR of 14.4% during the forecast period. Some of the key factors propelling the market growth are technological developments for nerve repair and regeneration and an increase in healthcare expense

Business Wire | August 10, 2020

Nevro Corp (NVRO) CEO Keith Grossman on Q2 2020 Results - Earnings Call Transcript

Nevro Corp (NVRO) Q2 2020 Earnings Conference Call August 05, 2020, 16:30 ET Company Participants Juliet Cunningham - VP, IR Keith Grossman - Chairman, CEO & President Roderick MacLeod - CFO Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Chase & Co. David Lewis -...

SA Transcripts on Seeking Alpha | August 6, 2020

Read More 'NVRO' Stories Here

NVRO Price Returns

1-mo 15.20%
3-mo 22.86%
6-mo 36.17%
1-year 51.84%
3-year 129.54%
5-year 211.76%
YTD 45.51%
2019 202.24%
2018 -43.67%
2017 -4.98%
2016 7.63%
2015 74.58%

Continue Researching NVRO

Here are a few links from around the web to help you further your research on Nevro Corp's stock as an investment opportunity:

Nevro Corp (NVRO) Stock Price | Nasdaq
Nevro Corp (NVRO) Stock Quote, History and News - Yahoo Finance
Nevro Corp (NVRO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8883 seconds.